Cecilia has vast experience within investor relations from positions within publicly listed companies in the biotech industry, including Abliva, Active Biotech, and most recently at Alligator Bioscience.
FREMONT, CA: BioInvent International AB, a biotech company focused on the discovery and development of novel and best-in-class immune-modulatory antibodies for cancer immunotherapy, has declared the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent encompassing external communications as well as investor relations. She would take office within three months and report directly to CEO Martin Welschof.
Cecilia has vast experience within investor relations from positions within publicly listed companies in the biotech industry, including Abliva, Active Biotech, and most recently at Alligator Bioscience. She has achieved a B.Sc in Chemistry and Molecular Biology from Lund University and has also completed the Communication Executive Program at the Stockholm School of Economics. Besides IR and Communication, Cecilia Hofvander also has experience in business development and international clinical drug trials.
"We are pleased to recruit Cecilia to the BioInvent team," stated Martin Welschof, CEO of BioInvent. "She has broad experience from both investor relations and from the science field, a welcome addition to our team as BioInvent advances its position within the immune therapy area and builds international relationships."
"I am delighted of the opportunity to join BioInvent and to be part of its exciting journey. BioInvent has an expanding clinical portfolio within immuno-oncology, an area which over the past decade has emerged as a novel and important approach to cancer treatment," stated Cecilia Hofvander. "I look forward to joining Martin and his team to contribute further to communication openness and clarity as a means of building long-term relationships with the company's stakeholders."